A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts

Thyroid

Volumn 22, Issue 8, 2012, Pages 839-843

  Neumann, Susanne ^a   Pope, Arthur ^a   Geras Raaka, Elizabeth ^a   Raaka, Bruce M ^a   Bahn, Rebecca S ^b   Gershengorn, Marvin C ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CYCLIC AMP; FORSKOLIN; HORMONE RECEPTOR BLOCKING AGENT; MESSENGER RNA; NCGC 00229600; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ADIPOCYTE; ARTICLE; CELL DIFFERENTIATION; CELL STRUCTURE; CONTROLLED STUDY; ENDOCRINE OPHTHALMOPATHY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID VESICLE; PRIORITY JOURNAL; THYROID CELL;

ADIPOCYTES; CYCLIC AMP; FIBROBLASTS; GRAVES DISEASE; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; PYRIDINES; QUINAZOLINONES; RECEPTORS, THYROTROPIN;

EID: 84864672538     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0520     Document Type: Article

References (19)

1. Bahn RS 2010 Graves' ophthalmopathy. N Engl J Med 362:726-738.
2. Wiersinga WM 2011 Autoimmunity in Graves' ophthalmopathy: The result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab 96:2386-2394.
3. Smith TJ 2010 Pathogenesis of Graves' orbitopathy: A 2010 update. J Endocrinol Invest 33:414-421.
4. Zhao SX, Tsui S, Cheung A, Douglas RS, Smith TJ, Banga JP 2011 Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol 210:369-377.
5. Baker G, Mazziotti G, von Ruhland C, Ludgate M 2005 Reevaluating thyrotropin receptor-induced mouse models of Graves' disease and ophthalmopathy. Endocrinology 146: 835-844.
6. Neumann S, Eliseeva E, McCoy JG, Napolitano G, Giuliani C, Monaco F, Huang W, Gershengorn MC 2011 A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor. J Clin Endocrinol Metab 96: 548-554.
7. Neumann S, Huang W, Eliseeva E, Titus S, Thomas CJ, Gershengorn M 2010 A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. Endocrinology 151:3454-3459.
8. Neumann S, Kleinau G, Costanzi S, Moore S, Jiang JK, Raaka BM, Thomas CJ, Krause G, Gershengorn MC 2008 A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinology 149:5945-5950.
9. Van Koppen CJ, De Gooyer ME, Karstens WJ, Plate R, Conti PG, van Achterberg TA, van Amstel MG, Brands JH, Wat J, Berg RJ, Lane JR, Miltenburg AM, Timmers CM 2011 Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor. Br J Pharmacol 165:2314-2324.
10. Valyasevi RW, Erickson DZ, Harteneck DA, Dutton CM, Heufelder AE, Jyonouchi SC, Bahn RS 1999 Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab 84:2557-2562.
11. Guo N, Baglole CJ, O'Loughlin CW, Feldon SE, Phipps RP 2010 Mast cell-derived prostaglandin D2 controls hyaluronan synthesis in human orbital fibroblasts via DP1 activation: Implications for thyroid eye disease. J Biol Chem 285:15794-15804.
12. Starkey KJ, Janezic A, Jones G, Jordan N, Baker G, Ludgate M 2003 Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol 30:369-380.
13. Heufelder AE, Bahn RS 1992 Evidence for the presence of a functional TSH-receptor in retroocular fibroblasts from patients with Graves' ophthalmopathy. Exp Clin Endocrinol 100:62-67.
14. Crisp M, Starkey KJ, Lane C, Ham J, Ludgate M 2000 Adipogenesis in thyroid eye disease. Invest Ophthalmol Vis Sci 41:3249-3255.
15. Kumar S, Nadeem S, Stan MN, Coenen M, Bahn RS 2011 A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy. J Mol Endocrinol 46:155-163.
16. Zhang L, Bowen T, Grennan-Jones F, Paddon C, Giles P, Webber J, Steadman R, Ludgate M 2009 Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: Contributory role in hyaluronan accumulation in thyroid dysfunction. J Biol Chem 284: 26447-26455.
17. van Zeijl CJ, Van Koppen CJ, Surovtseva OV, De Gooyer ME, Plate R, Conti P, Karstens WJ, Timmers M, Saeed P, Wiersinga WM, Miltenburg AM, Fliers E, Boelen A 2012 Complete inhibition of rhTSH-, Graves' disease IgG-, and M22-induced cAMP production in differentiated orbital fibroblasts by a low-molecular-weight TSHR antagonist. J Clin Endocrinol Metab 97:E781-E785.
18. Neumann S, Gershengorn MC 2011 Small molecule TSHR agonists and antagonists. Ann Endocrinol (Paris) 72:74-76.
19. Emerson CH 2011 When will thyrotropin receptor antagonists and inverse thyrotropin receptor agonists become available for clinical use? Thyroid 21:817-819.